Watson-Marlow Fluid Technology Solutions launches WMArchitect single-use solutions to optimise biopharmaceutical fluid management

• The new range of WMArchitect single-use solutions is designed to streamline the process, safeguard products, and reduce regulatory burden for biopharmaceutical companies
• With an open architecture approach, WMArchitect offers both standard, ready-to-use single-use assemblies as well as customised designs
• WMArchitect offers complete confidence in product quality with WMFTS as a trusted and skilled extension of a company’s quality system

Falmouth, UK, 15th April 2023 / Sciad Newswire / Watson-Marlow Fluid Technology Solutions (WMFTS) has launched WMArchitectTM single-use solutions to offer a wide range of biopharmaceutical fluid management innovations from a single, secure supplier.

The flexible, single-use solutions range has been developed by building on years of experience including the predecessor brands of puresu® and asepticsu®, and is designed to streamline a biopharmaceutical company’s process, safeguard its product and reduce its regulatory burden.

WMFTS, a manufacturer of peristaltic pumps and associated fluid path technologies, is now offering customised designs from an extensive component library to meet a customer’s specifications, as well as a selection of standard, ready-to-use single-use assemblies.

WMArchitect is a new end-to-end, single-use fluid path management solution consisting of:

Customised designs – single-use assemblies are custom-designed to meet a company’s specific requirements. The open architecture model allows full flexibility and compatibility with existing fluid-contact materials used in a company’s bioprocess.  

Single-use fluid transfer assemblies are ready-to-use, pre-designed assemblies, all with lot traceable tubing and components, which optimise fluid transfer between equipment and process steps. They can be selected from a menu of validated components.

Fill/finish single-use assemblies that safeguard therapeutic products during the filling process with a wide range of sterility-assured assembly configurations. Representative assemblies are routinely tested for bioburden, particulates and endotoxin.

Validation testing specialists from WMFTS support users of WMArchitect with bioprocessing expertise and tailored validation packages to help reduce a company’s regulatory burden.

As a trusted partner and a highly skilled extension of a biopharmaceutical company’s quality system, WMFTS works with its customers to ensure complete confidence in product quality and sterility assurance.

Nicole Hunter, Head of Global WMArchitect, said: “By listening to the evolving needs of our biopharmaceutical customers, we have created WMArchitect to provide an expert solution that supports them in mitigating their regulatory and supply chain risks.

“WMFTS understands that often, off-the-shelf products are merely a starting point. We customise our standard products to provide a complete and tested solution from a single supplier that is tailored to meet a company’s specific requirements.

“WMArchitect is ideal for high purity biopharmaceutical process development, clinical trials and small to large scale production batches.

“We recognise that the most critical component for maximising performance is where the tubing meets the pump. Our assembly solutions are designed synergistically with our best-in-class Watson-Marlow peristaltic pump technologies and filling solutions. With quality built-in, our complete solutions ensure reliable, repeatable performance for your most sensitive processes.”

All WMArchitect single-use solutions are manufactured, pre-assembled and packaged at WMFTS’ global network of state-of-the-art Class 7 cleanrooms. The WMFTS global supply network provides uninterrupted supply security and robust lead times. By partnering with WMArchitect, biopharmaceutical companies can be confident that supply will keep pace as their business grows.

To ensure our single-use technology comes ready to use, and meets the requirements set by current good manufacturing practice (cGMP) guidelines, lot traceability of each component can be made available as part of our detailed documentation.      

For an end-to-end fluid management solution from a single supplier, WMArchitect can be used in combination with best-in-class BioPure components, Watson-Marlow and Flexicon peristaltic pump technologies and filling solutions.

A dedicated WMArchitect business unit and additional resources allow for rapid turn-around from a supplier that will keep pace as their customers business grows.

Benefits and features

• Complete confidence in product quality
• Designed to reduce a biopharmaceutical company’s validation burden  
• Support of internal validation protocols
• Flexible integration with an open architecture approach
• Use in conjunction with Watson-Marlow peristaltic pumps or Flexicon filling systems for an end-to-end fluid management solution 
• Supply security with WMFTS’ global manufacturing and supply network

ENDS

For further information, please contact:

Lauren Gill, PR Manager  
Watson-Marlow Fluid Technology Solutions  
E: Lauren.gill@wmfts.com

Sciad Communications, Media Relations  
Juliette Craggs / Jasmin Shearan 
E: watsonmarlow@sciad.com
T: +44 (0)20 3405 7892  

Notes for Editors

About Watson-Marlow Fluid Technology Solutions

Watson-Marlow Fluid Technology Solutions (WMFTS) is a world leader in manufacturing peristaltic pumps and associated fluid path technologies for the life sciences and process industries.

The company offers a wide range of peristaltic pumps and associated fluid path technologies, including tubing, specialised filling systems and products for single-use applications.

WMFTS is a wholly owned subsidiary of Spirax Group (formerly Spirax-Sarco Engineering plc), with 47 operating units worldwide (December 31, 2023).

Further information can be found at www.wmfts.com.